Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert L Wortmann

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
The Journal of Rheumatology|November 7, 2009
Hydroxychloroquine and colchicine induced myopathyTimothy A Lonesky, Justin D Kreuter, Robert L Wortmann, et al.
The American Journal of Cardiology|April 12, 2005
Frequency of myopathy in patients receiving lovastatinRobert L Wortmann, Robert W Tipping, Jeffrey G Levine, et al.
Current Opinion in Rheumatology|September 6, 2014
The causes of drug-induced muscle toxicityJonathan D Jones, Hannah L Kirsch, Robert L Wortmann, et al.
The Journal of Rheumatology|November 18, 2009
Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USABrendan B Antiochos, Lin A Brown, Zhongze Li, et al.
Molecular Genetics and Metabolism|July 29, 2011
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathiesGeorgirene D Vladutiu, Paul J Isackson, Kenneth Kaufman, et al.
Arthritis and Rheumatism|November 1, 2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trialH Ralph Schumacher, Michael A Becker, Robert L Wortmann, et al.
Arthritis and Rheumatism|March 8, 2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The New England Journal of Medicine|December 13, 2005
Febuxostat compared with allopurinol in patients with hyperuricemia and goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
Arthritis Care & Research|October 29, 2011
When should a rheumatologist suspect a mitochondrial myopathy?Daniel A Albert, Jeffrey A Cohen, Christopher M Burns, et al.
Muscle & Nerve|May 4, 2006
Genetic risk factors associated with lipid-lowering drug-induced myopathiesGeorgirene D Vladutiu, Zachary Simmons, Paul J Isackson, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
The Journal of Rheumatology|November 7, 2009
Hydroxychloroquine and colchicine induced myopathyTimothy A Lonesky, Justin D Kreuter, Robert L Wortmann, et al.
The American Journal of Cardiology|April 12, 2005
Frequency of myopathy in patients receiving lovastatinRobert L Wortmann, Robert W Tipping, Jeffrey G Levine, et al.
Current Opinion in Rheumatology|September 6, 2014
The causes of drug-induced muscle toxicityJonathan D Jones, Hannah L Kirsch, Robert L Wortmann, et al.
The Journal of Rheumatology|November 18, 2009
Malignancy is associated with dermatomyositis but not polymyositis in Northern New England, USABrendan B Antiochos, Lin A Brown, Zhongze Li, et al.
Molecular Genetics and Metabolism|July 29, 2011
Genetic risk for malignant hyperthermia in non-anesthesia-induced myopathiesGeorgirene D Vladutiu, Paul J Isackson, Kenneth Kaufman, et al.
Arthritis and Rheumatism|November 1, 2008
Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trialH Ralph Schumacher, Michael A Becker, Robert L Wortmann, et al.
Arthritis and Rheumatism|March 8, 2005
Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
The New England Journal of Medicine|December 13, 2005
Febuxostat compared with allopurinol in patients with hyperuricemia and goutMichael A Becker, H Ralph Schumacher, Robert L Wortmann, et al.
Arthritis Care & Research|October 29, 2011
When should a rheumatologist suspect a mitochondrial myopathy?Daniel A Albert, Jeffrey A Cohen, Christopher M Burns, et al.
Muscle & Nerve|May 4, 2006
Genetic risk factors associated with lipid-lowering drug-induced myopathiesGeorgirene D Vladutiu, Zachary Simmons, Paul J Isackson, et al.
Pageof 4